{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:56:26Z","timestamp":1740149786171,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s12328-020-01103-w","type":"journal-article","created":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T13:05:55Z","timestamp":1581944755000},"page":"896-901","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful treatment with glecaprevir\/pibrentasvir for chronic hepatitis C complicated by primary biliary cholangitis"],"prefix":"10.1007","volume":"13","author":[{"given":"Satoshi","family":"Takakusagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yozo","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Marubashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Kizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kosone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0224-7093","authenticated-orcid":false,"given":"Satoru","family":"Kakizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Uraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,17]]},"reference":[{"key":"1103_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00535-017-1391-5","volume":"53","author":"K Chayama","year":"2018","unstructured":"Chayama K, Suzuki F, Karino Y, et al. Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol. 2018;53:557\u201365.","journal-title":"J Gastroenterol"},{"key":"1103_CR2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/hep.29510","volume":"67","author":"H Toyoda","year":"2018","unstructured":"Toyoda H, Chayama K, Suzuki F, et al. Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology. 2018;67:505\u201313.","journal-title":"Hepatology"},{"key":"1103_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00281-012-0328-6","volume":"35","author":"D Vergani","year":"2013","unstructured":"Vergani D, Mieli-Vergani G. Autoimmune manifestations in viral hepatitis. Semin Immunopathol. 2013;35:73\u201385.","journal-title":"Semin Immunopathol"},{"key":"1103_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1586\/1744666X.2015.997214","volume":"11","author":"AL Zignego","year":"2015","unstructured":"Zignego AL, Gragnani L, Piluso A, et al. Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection. Expert Rev Clin Immunol. 2015;11:15\u2013311.","journal-title":"Expert Rev Clin Immunol"},{"key":"1103_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1665-2681(19)30914-7","volume":"13","author":"EI Rigapoulou","year":"2013","unstructured":"Rigapoulou EI, Zochou K, Gatselis N, et al. Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. Ann Hepatol. 2013;13:127\u201335.","journal-title":"Ann Hepatol"},{"key":"1103_CR6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.4254\/wjh.v5.i10.577","volume":"5","author":"EI Rigopoulou","year":"2013","unstructured":"Rigopoulou EI, Zachou K, Gatselis NK, et al. Primary biliary cirrhosis in HBV and HCV patients: clinical characteristics and outcome. World J Hepatol. 2013;5:577\u201383.","journal-title":"World J Hepatol"},{"key":"1103_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1665-2681(19)31388-2","volume":"12","author":"HW Chen","year":"2013","unstructured":"Chen HW, Huang HH, Lai CH, et al. Hepatitis C virus infection in patients with primary biliary cirrhosis. Ann Hepatol. 2013;12:78\u201384.","journal-title":"Ann Hepatol"},{"key":"1103_CR8","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1111\/j.1572-0241.2003.08717.x","volume":"98","author":"A Floreani","year":"2003","unstructured":"Floreani A, Baragiotta A, Leone MG, et al. Primary biliary cirrhosis and hepatitis C infection. Am J Gastroenterol. 2003;98:2757\u201362.","journal-title":"Am J Gastroenterol"},{"key":"1103_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1159\/000475752","volume":"11","author":"A Sugiura","year":"2017","unstructured":"Sugiura A, Wada S, Mori H, et al. Successful treatment for chronic hepatitis C -autoimmune hepatitis overlap syndrome due to daclatasvir and asunaprevir. Case Rep Gastroenterol. 2017;11:305\u201311.","journal-title":"Case Rep Gastroenterol"},{"key":"1103_CR10","doi-asserted-by":"publisher","first-page":"11631","DOI":"10.18632\/oncotarget.24391","volume":"9","author":"T Kanda","year":"2018","unstructured":"Kanda T, Yasui S, Nakamura M, et al. Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precaution for deterioration of autoimmune hepatitis. Oncotarget. 2018;9:11631\u20137.","journal-title":"Oncotarget"},{"key":"1103_CR11","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/hep4.1248","volume":"2","author":"G Covini","year":"2018","unstructured":"Covini G, Bredi E, Badalamenti S, et al. Autoimmune hepatitis during ledipasvir\/sofosbuvir treatment of hepatitis C: a case report. Hepatol Commun. 2018;2:1179\u201383.","journal-title":"Hepatol Commun"},{"key":"1103_CR12","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1007\/BF02065528","volume":"40","author":"T Maeda","year":"1995","unstructured":"Maeda T, Onishi S, Miura T, et al. Exacerbation of primary biliary cirrhosis during interferon-\u03b12b therapy for chronic active hepatitis C. Dig Dis Sci. 1995;40:1226\u2013300.","journal-title":"Dig Dis Sci"},{"key":"1103_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S0928-4346(96)00325-8","volume":"6","author":"F Ichida","year":"1996","unstructured":"Ichida F, Tsuji T, Omata M, et al. New Inuyama classification: new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun. 1996;6:112\u20139.","journal-title":"Int Hepatol Commun"},{"key":"1103_CR14","first-page":"1257","volume":"60","author":"PJ Scheuer","year":"1967","unstructured":"Scheuer PJ. Primary biliary cirrhosis. Proc R Soc Med. 1967;60:1257\u201360.","journal-title":"Proc R Soc Med"},{"key":"1103_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/BF00432479","volume":"379","author":"J Ludwig","year":"1978","unstructured":"Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol. 1978;379:103\u201312.","journal-title":"Virchows Arch A Pathol Anat Histol"},{"key":"1103_CR16","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","volume":"31","author":"F Alvarez","year":"1999","unstructured":"Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group report; review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929\u201338.","journal-title":"J Hepatol"},{"key":"1103_CR17","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hep.510280203","volume":"28","author":"O Chazouill\u00e8res","year":"1998","unstructured":"Chazouill\u00e8res O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology. 1998;28:296\u2013301.","journal-title":"Hepatology"},{"unstructured":"Drafting committee for hepatitis management guidelines, the Japan society of hepatology. [JSH guidelines for the management of hepatitis C virus infection (version 7)]. https:\/\/www.jsh.or.jp\/files\/uploads\/HCV_GL_ver7_02.pdf","key":"1103_CR18"},{"key":"1103_CR19","doi-asserted-by":"publisher","first-page":"9880","DOI":"10.3748\/wjg.v22.i45.9880","volume":"22","author":"RN Karanjia","year":"2016","unstructured":"Karanjia RN, Crossey MM, Cox IJ, et al. Hepatic steatosis and fibrosis: Non-invasive assessment. World J Gastroenrerol. 2016;22:9880\u2013977.","journal-title":"World J Gastroenrerol"},{"key":"1103_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00535-002-1090-7","volume":"38","author":"H Sezaki","year":"2003","unstructured":"Sezaki H, Arase Y, Tsubota A, et al. Type C-chronic hepatitis patients who had autoimmune phenomenon and developed jaundice during interferon therapy. J Gastroenterol. 2003;38:493\u2013500.","journal-title":"J Gastroenterol"},{"key":"1103_CR21","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.2169\/internalmedicine.53.3194","volume":"53","author":"N Mori","year":"2014","unstructured":"Mori N, Imamura M, Takaki S, et al. Hepatitis virus (HCV) reactivation caused by steroid therapy for dermatomyositis. Intern Med. 2014;53:2689\u201393.","journal-title":"Intern Med"},{"key":"1103_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12876-018-0826-7","volume":"18","author":"HH Nguyen","year":"2018","unstructured":"Nguyen HH, Khathlan A, Fritzler MJ, et al. A case series evaluating the impact of Hepatitis C eradication using direct acting antivirals on primary biliary cholangitis-associated autoimmunity. BMC Gastroenterol. 2018;18:97.","journal-title":"BMC Gastroenterol"},{"key":"1103_CR23","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00431-006-0267-0","volume":"166","author":"H Tajiri","year":"2007","unstructured":"Tajiri H, Etani Y, Mushiake S, et al. Acute exacerbation of hepatitis in a boy with chronic HCV genotype-2 infection after a 9-year period of normal transaminases levels. Eur J Pediatr. 2007;166:501\u20132.","journal-title":"Eur J Pediatr"},{"key":"1103_CR24","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.cgh.2013.03.025","volume":"11","author":"E Sagnelli","year":"2013","unstructured":"Sagnelli E, Pisaturo M, Stanzione M, et al. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol. 2013;11:1174\u201380.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1103_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/jmv.24595","volume":"89","author":"JW Lin","year":"2017","unstructured":"Lin JW, Chang ML, Hsu CW, et al. Acute exacerbation of hepatitis C in hepatocellular carcinoma patients receiving chemotherapy. J Med Virol. 2017;89:153\u201360.","journal-title":"J Med Virol"},{"key":"1103_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10620-006-3083-5","volume":"51","author":"T Kanda","year":"2006","unstructured":"Kanda T, Yokosuka O, Hirasawa Y, et al. Occurrence of autoimmune hepatitis during the course of primary biliary cirrhosis: report of two cases. Dig Dis Sci. 2006;51:45\u20136.","journal-title":"Dig Dis Sci"},{"key":"1103_CR27","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1097\/TP.0000000000001606","volume":"101","author":"JM Werner","year":"2017","unstructured":"Werner JM, Adenugba A, Protzer U, et al. Immune reconstitution after HCV clearance with direct antiviral agents: Potential consequences for patients with HCC? Transplantation. 2017;101:904\u20139.","journal-title":"Transplantation"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-020-01103-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12328-020-01103-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-020-01103-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T23:57:13Z","timestamp":1613692633000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12328-020-01103-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,17]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1103"],"URL":"https:\/\/doi.org\/10.1007\/s12328-020-01103-w","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"type":"print","value":"1865-7257"},{"type":"electronic","value":"1865-7265"}],"subject":[],"published":{"date-parts":[[2020,2,17]]},"assertion":[{"value":"7 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"K. Sato received research funding from AbbVie. S. Kakizaki received research funding from BMS and Gilead.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights"}},{"value":"Informed consent was obtained from the patient of this report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}